
Nephrotic Syndrome Market Size, Share, Trends & Global Forecast 2026-2035
The Nephrotic Syndrome Market is Segmented By Drugs (Sodium Restriction Drugs, Fluid Restriction Drugs, Loop Diuretics, Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Therapy, and Others), By Diagnosis Tests (Urinalysis, Glomerular Filtration Rate (GFR), Blood Test, Kidney Biopsy, and Computerized Tomography (CT) Scan), By End Users (Clinics, Hospitals, Speciality Centres, and Others) and Region
Nephrotic Syndrome Market Overview and Definition
The Global Nephrotic Syndrome Market was valued at approximately USD 0.96–1.05 Billion in 2025, and is projected to reach USD 2.1–2.5 Billion by 2035, growing at a CAGR of 10.70% from 2026 to 2035. Rising prevalence of diabetes and hypertension, increasing incidence of kidney disease, and expanding adoption of advanced diagnostic screening programmes drive market expansion across developed and emerging economies. Loop diuretics and angiotensin receptor blocker therapies dominate pharmacological treatment, whilst urinalysis and glomerular filtration rate testing remain primary diagnostic modalities.
Healthcare infrastructure modernisation across Asia-Pacific and emerging markets creates multi-year demand growth for diagnostic and therapeutic capabilities. Novel immunosuppressive therapies and precision-medicine approaches targeting specific disease pathologies represent emerging growth segments. North America dominates market with largest treatment population, whilst Asia-Pacific emerges as fastest-growing region driven by rising diabetes prevalence and healthcare investment. Strategic regulatory approvals, clinical-trial expansion, and pharmaceutical pipeline advancement define competitive landscape transformation.
Key Market Trends & Analysis
- Global Nephrotic Syndrome Market valued at approximately USD 1.0 billion in 2025, reflecting chronic kidney disease treatment demand.
- Market projected to reach USD 2.1–2.5 billion by 2035, representing substantial healthcare infrastructure investment opportunity.
- Global CAGR of 10.70% from 2026 to 2035 underpinned by rising diabetes prevalence and aging populations globally.
- Seven major markets (USA, EU4, UK, Japan) totalled approximately USD 400 million in 2025, representing mature healthcare market concentration.
- Diagnosed prevalent cases in seven major markets approximately 800,000 in 2025, expected to increase during forecast period.
- United States accounts for largest treatment market, representing approximately 50% of seven-major-market revenue in 2025.
- EU4 countries plus United Kingdom market valued at approximately USD 140 million in 2025, supported by advanced diagnostics and therapeutics.
- Asia-Pacific emerges as fastest-growing region, driven by rising diabetes incidence and healthcare infrastructure modernisation.
- Loop diuretics capture largest drug category share, whilst novel therapies including sparsentan show highest growth trajectory.
- April 2026 FDA approval of Filspari (sparsentan) for focal segmental glomerulosclerosis represents major therapeutic advancement.
- Filspari achieved USD 141 million in first-year sales with 96% year-over-year growth, validating market demand for novel therapeutics.
- Clinical trial registrations surge with over 30% registered in 2025, reflecting intensified research and development activity.
The nephrotic syndrome market consists of drugs, diagnostics and medical devices used for treating Nephrotic Syndrome and kidney disease. The drugs within this market include loop diuretics to reduce fluid retention and proteinuria, renoprotective drugs such as angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Immunosuppressants are also used including steroids and new biological drugs. Medications to reduce sodium and fluids are also available along with supportive treatments.
Diagnostic tests include urine testing to identify proteinuria, GFR tests, blood tests to assess kidney biomarkers and disease activity and kidney biopsies. These can be used in an outpatient setting, inpatient departments, nephrology centres and dialysis centres. The key players within this market would be drug manufacturers, diagnostics laboratories, medical device manufacturers, healthcare facilities and renal specialists. This market is focused on addressing unmet medical needs in patients suffering from Immunoglobulin A nephropathy, focal segmental glomerulosclerosis, membranous nephropathy and secondary nephrotic syndrome caused by systemic lupus erythematosus and diabetes mellitus.
Nephrotic Syndrome treatment is a key area for renal specialists and healthcare systems due to the increasing prevalence of chronic kidney disease and its complications. As secondary nephrotic syndrome caused by diabetes is increasing there is an urgent need for effective disease modifying drugs to reduce proteinuria. New immunosuppressant drugs and precision medicine have made a significant improvement in treating this condition compared to traditional steroid treatments which cause significant side effects. Sparsentan has been approved by the regulator and several drugs are in the pipeline meaning there are viable options to treat nephrotic syndrome.
Source: Kaiso Research and Consulting
There is pressure on healthcare systems to reduce costs of nephrotic syndrome due to the requirement for dialysis and transplants meaning there is a desire for early disease modifying treatments. An ageing population and increase in obesity related metabolic syndrome means there will be increased demand for diagnosing and treating kidney diseases over the next few years. There is an increase in clinical trials and global research meaning there is innovation in understanding and developing treatments for rare kidney diseases. There is therefore a positive outlook as the prevalence of diseases is increasing, drugs are being approved quicker and there are more viable options within the specialty nephrology space.
In April 2026, the United States Food and Drug Administration approved Travere Therapeutics' Filspari (sparsentan) for reducing proteinuria in focal segmental glomerulosclerosis patients without nephrotic-range proteinuria, representing first selective endothelin receptor antagonist approval for kidney disease.
Recent Developments in the Nephrotic Syndrome Market
- In April 2026, the United States Food and Drug Administration approved Travere Therapeutics' Filspari (sparsentan) for reducing proteinuria in focal segmental glomerulosclerosis patients aged eight years and older. The approval followed accelerated regulatory pathway driven by clinical efficacy data demonstrating proteinuria reduction and renal-function preservation. Filspari achieved USD 141 million in net product sales during initial eight-month commercial period, with 96% year-over-year growth reflecting strong physician adoption and patient uptake across focal segmental glomerulosclerosis and immunoglobulin A nephropathy indications. Commercial success validates market demand for targeted therapies beyond traditional immunosuppressive regimens.
- In June 2026, Travere Therapeutics signed a licensing agreement with Everest Medicines for commercialisation rights of civorebrutinib, a selective Bruton's tyrosine kinase inhibitor, outside China and parts of East and Southeast Asia. The partnership expands Travere's rare kidney disease pipeline whilst providing geographic expansion pathway for emerging nephrology therapeutics. Strategic partnership reflects industry consolidation and geographic expansion strategies among specialty pharmaceutical companies targeting underserved kidney disease populations.
- In April 2026, Climb Bio received Fast Track designation from the United States Food and Drug Administration for budoprutug, a potential first-in-class IRAK4 inhibitor, indicated for treatment of primary membranous nephropathy. Fast Track status provides expedited regulatory pathway reflecting unmet clinical need in membranous nephropathy treatment. The designation accelerates development timeline for novel mechanism-of-action therapy addressing immunologically-mediated glomerular disease.
- In March 2025, the United States Food and Drug Administration expanded approval of Furoscix (furosemide injection) to include treatment of oedema in patients with chronic kidney disease, including nephrotic syndrome. The expanded indication provides convenient at-home diuretic administration option for nephrotic syndrome patients managing fluid overload. Approval expansion broadens patient access to loop diuretic therapy beyond hospital and clinic administration settings.
- In September 2026, Avenacy announced United States commercial launch of Cyclophosphamide for Injection, United States Pharmacopeia, an FDA-approved therapeutic generic equivalent to Cytoxan (cyclophosphamide for injection). The generic launch provides cost-effective immunosuppressive option for nephrotic syndrome patients requiring cytotoxic therapy. Generic availability expands treatment access for patients in developing-economy settings where brand-name immunosuppressive agents remain cost-prohibitive.
Nephrotic Syndrome Market Dynamics: Drivers, Restraints, Opportunities, Challenges and Trends
Drivers: Rising diabetes prevalence and aging populations drive nephrotic syndrome market expansion substantially.
Diabetes mellitus represents leading cause of secondary nephrotic syndrome in developed economies, with type-2 diabetes expansion across emerging markets directly increasing disease incidence. Global diabetes prevalence affecting approximately 540 million individuals creates massive patient pool at risk for diabetic kidney disease progression to nephrotic syndrome. Hypertension-associated chronic kidney disease represents additional major disease driver affecting approximately one billion individuals worldwide. Obesity-associated metabolic syndrome and lifestyle factors accelerate kidney disease progression rates, expanding addressable patient population requiring nephrotic syndrome treatment.
Aging population demographics across developed economies increase disease prevalence through accumulated comorbidity burden and age-related glomerular sclerosis. Healthcare infrastructure modernisation and improved diagnostic screening capabilities enable earlier disease identification and treatment initiation. Rising healthcare expenditure in emerging economies improves access to kidney disease diagnostics and pharmaceutical treatments previously unavailable in developing regions.
Restraints: Limited treatment efficacy and substantial side-effect burdens constrain nephrotic syndrome therapy adoption.
Traditional immunosuppressive regimens including high-dose corticosteroids carry substantial adverse-effect risks including infection susceptibility, metabolic complications, and psychiatric effects limiting patient tolerability and treatment persistence. Kidney disease progression toward end-stage renal disease remains common outcome despite contemporary treatment, creating psychological and economic barriers to patient engagement. Diagnostic complexity requiring kidney biopsy procedures for definitive disease classification limits screening frequency and early intervention opportunities.
Limited understanding of pathogenic mechanisms in primary glomerular diseases constrains development of targeted therapies addressing underlying disease biology. Treatment costs for specialty immunosuppressive agents and management of complications create substantial out-of-pocket expenses for patients in resource-limited healthcare systems. Regulatory stringency surrounding immunosuppressive drug approvals extends development timelines and increases commercialisation costs for novel nephrology therapeutics. Limited awareness among primary-care physicians regarding nephrotic syndrome diagnosis and management delays disease recognition and treatment initiation.
Opportunities: Novel immunosuppressive therapies and precision-medicine approaches create high-growth commercial opportunities.
Selective endothelin receptor antagonists including sparsentan provide non-immunosuppressive mechanism targeting proteinuria reduction with improved safety profiles versus traditional corticosteroid regimens. Bruton's tyrosine kinase inhibitors including civorebrutinib address immunologically-mediated glomerular diseases through novel B-cell pathway targeting. Complement-pathway inhibitors and alternative-pathway targeted therapies address immune-complex glomerulonephritis through mechanism-specific intervention. Biomarker-driven patient stratification enabling precision-medicine approaches targeting specific disease subtypes creates commercial differentiation and premium-pricing opportunities.
Digital health platforms and remote monitoring capabilities enabling at-home disease management support patient engagement and treatment adherence. Emerging-market expansion opportunities across Asia-Pacific and Latin America present greenfield patient populations with rising diabetes prevalence and expanding healthcare infrastructure. Combination therapy approaches pairing novel mechanisms with traditional renoprotective agents address disease heterogeneity and create barriers to competitive entry through intellectual-property protection.
Challenges: Regulatory approval delays and payer reimbursement barriers constrain new therapy commercialisation.
Lengthy clinical-trial timelines required for immunoglobulin A nephropathy and membranous nephropathy studies delay therapy approval by five to ten years relative to other therapeutic domains. Regulatory requirement for kidney biopsy-confirmed diagnosis limits trial-recruitment feasibility and increases trial costs. Payer hesitancy regarding specialty pharmaceutical pricing creates reimbursement barriers for novel nephrotic syndrome therapies. Budget-impact concerns within healthcare systems limit adoption of expensive immunosuppressive agents despite efficacy advantages over traditional approaches.
Limited patient awareness of nephrotic syndrome diagnosis and available treatment options constrains demand for novel therapies despite clinical advantages. Competitive intensity from generic immunosuppressive agents reduces pricing power for novel specialty nephrology drugs. Small patient populations in rare kidney disease subtypes limit commercial addressable market size relative to pharmaceutical development investment requirements.
Trends: Regulatory acceleration and precision-medicine technology integration drive industry innovation substantially.
Expedited regulatory pathways including Fast Track designation and breakthrough-therapy designation accelerate approval timelines for targeted nephrotic syndrome therapeutics addressing unmet clinical needs. Biomarker-driven patient stratification enables precision-medicine approaches targeting disease phenotypes with highest therapeutic responsiveness. Digital health platform adoption including remote patient monitoring and telemedicine consultation expand specialist access to underserved populations.
Clinical-trial innovation using patient-centric endpoints and adaptive trial designs accelerates drug development velocity. Combination therapy development pairing mechanism-specific interventions with traditional renoprotective agents reflects industry shift toward multi-targeted disease management. International research collaboration expansion including NEPTUNE initiative accelerates kidney disease epidemiology understanding and therapeutic target identification. Real-world evidence generation and health-outcomes research demonstrating therapy value proposition supports reimbursement case-building for novel nephrology therapeutics.
Where Are the Biggest Opportunities in the Nephrotic Syndrome Market?
- Mechanism-specific immunosuppressive therapies targeting primary glomerular disease pathologies addressing unmet treatment needs.
- Biomarker-driven patient stratification enabling precision-medicine approaches and premium-pricing positioning for targeted therapies.
- Emerging-market expansion across Asia-Pacific and Latin America capturing rising diabetes-driven nephrotic syndrome incidence.
- Combination therapy development pairing novel mechanisms with traditional renoprotective agents addressing disease heterogeneity.
- Digital health platform integration enabling remote monitoring, at-home care delivery, and patient engagement optimisation.
- Rare kidney disease specialisation targeting immunoglobulin A nephropathy, membranous nephropathy, and focal segmental glomerulosclerosis.
- Complement-pathway targeted therapeutics addressing immune-complex glomerulonephritis and membranoproliferative glomerulonephritis subtypes.
- Generic immunosuppressive production and distribution expansion across emerging markets reducing treatment cost barriers.
- Point-of-care diagnostic development enabling nephrotic syndrome screening and monitoring at primary-care settings.
- Disease-awareness and physician-education programmes expanding diagnosis rates in underdiagnosed emerging-market populations.
Nephrotic Syndrome Market Segmentation Analysis
Report Attributes | Details |
Market Size in 2025 | USD 0.96–1.05 Billion |
Market Size by 2035 | USD 2.1–2.5 Billion |
CAGR (2026-2035) | 10.70% |
Base Year | 2025 |
Forecast Period | 2026-2035 |
Historical Data | 2022-2024 |
Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, Analysis, Forecast Outlook |
Key Segments | By Drugs: Sodium Restriction Drugs, Fluid Restriction Drugs, Loop Diuretics, Angiotensin-Converting Enzyme Inhibitor (or Angiotensin Receptor Blocker Therapy), and Others By Diagnosis Tests: Urinalysis, Glomerular Filtration Rate (GFR), Blood Test, Kidney Biopsy, and Computerized Tomography (CT) Scan By End Users: Clinics, Hospitals, Speciality Centres, and Others |
Regional Analysis/Coverage | North America (U.S., Canada, Mexico), Europe (UK, Germany, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea, Rest of Asia-Pacific), LAMEA (Brazil, Argentina, UAE, Saudi Arabia, Africa, Rest of Latin America) |
Company Profiles | Abbott (U.S.), Travere Therapeutics, Inc. (U.S.), Novartis AG (Switzerland), Mallinckrodt company (U.S.), Pfizer Inc. (U.S.), Aurinia Pharmaceuticals Inc. (Canada), Orbis Biosciences Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), GSK Plc (U.K.), Asahi Kasei Corporation (Japan) |
Source: Kaiso Research and Consulting
Nephrotic Syndrome Market Segment Analysis
- By Drugs, Loop Diuretics dominated the Nephrotic Syndrome Market in 2025 with approximately 38% share; Angiotensin-Converting Enzyme Inhibitor (ACE-I) or Angiotensin Receptor Blocker (ARB) Therapy is the fastest-growing segment with a CAGR of approximately 11.5% from 2026 to 2035.
- By Diagnosis Tests, Urinalysis dominated the Nephrotic Syndrome Market in 2025 with approximately 42% share; Glomerular Filtration Rate (GFR) Testing is the fastest-growing segment with a CAGR of approximately 11.2% from 2026 to 2035.
- By End User, Hospitals dominated the Nephrotic Syndrome Market in 2025 with approximately 48% share; Specialty Centres is the fastest-growing segment with a CAGR of approximately 11.8% from 2026 to 2035.
Dominating Segments in the Nephrotic Syndrome Market
By Drugs: Loop diuretics establish market dominance through primary clinical-management role in nephrotic syndrome treatment.
Loop diuretics dominated the pharmaceutical market for nephrotic syndrome in 2025, accounting for ~38% of market share. These are currently widely used across different disease aetiologies due to well-established treatment protocols, furosemide and other loop diuretics are affordable drugs that are commonly used. Due to the use of these drugs globally there is still a strong lead in this segment however new mechanism specific therapies are available. Angiotensin-Converting Enzyme Inhibitors (ACE-Is) and Angiotensin Receptors Blockers (ARBs) are the fastest growing drug category.
From 2026-2035 they are estimated to have a CAGR of ~11.5%. This is because there has been more awareness about the renoprotective benefits of these drugs. ACE-Is and ARBs help reduce the progression of both diabetic and non-diabetic kidney disease through affecting glomerular haemodynamics and reducing inflammatory pathways. Their use is increasing in patients with nephrotic syndromes without hypertension, and also through combination therapy with novel immunosuppressive drugs. Sodium and fluid restriction is an important aspect of management. These drugs help manage fluid retention and can help increase the efficacy of diuretics.
In March 2025, the United States Food and Drug Administration expanded approval of Furoscix (furosemide injection) to include nephrotic syndrome oedema treatment, expanding at-home diuretic administration options and supporting patient convenience and treatment adherence.
By Diagnosis Tests: Urinalysis maintains market leadership through fundamental diagnostic utility and universal accessibility.
The Urinalysis segment accounts for about 42% of the diagnostic market for nephrotic syndrome in 2025. It is an important test used to detect proteins in urine and begin investigations for glomerular diseases. The point of care test can be used quickly in an outpatient setting. Due to its cost-effectiveness, ease of use and availability, it is still widely used in healthcare settings, even in those that have limited resources.
The Glomerular Filtration Rate (GFR) segment is seeing the fastest growth. This will grow at a CAGR rate of ~11.2% between 2026 and 2035. More attention has been placed on monitoring kidney function and assessing progression of disease. Cystatin-c based tests for estimating GFR and new biomarker techniques are providing extra functionality. This has increased their importance within clinical practice meaning there is increased demand for comprehensive diagnostic testing.
The Kidney Biopsy segment is being used due to the ability to confirm pathology for the use of targeted immunosuppressants. Histological testing can help to provide insight into the underlying glomerular pathology. Advanced imaging such as Computerised Tomography (CT) scans can also help to give insight into the structure of the kidneys. This helps to identify complications and monitor response to treatment.
In June 2026, Travere Therapeutics announced clinical trial results demonstrating sparsentan-induced proteinuria reduction correlating with improved glomerular filtration rate trajectories, validating dual-biomarker approach to nephrotic syndrome monitoring and disease-activity assessment.
By End User: Hospitals dominate through acute-decompensation management and inpatient dialysis requirements.
Hospitals have contributed to the highest amount of revenue in this market (around 48%) due to acute complications requiring management within these settings. Patients can often present with acute kidney injury, thrombosis and infections which may require treatment and monitoring within the hospital. Patients will also often progress to require dialysis if reaching end stage renal disease, therefore contributing to revenues generated within hospitals.
Specialty nephrology centres are the fastest growing segment, with an expected CAGR of around 11.8% from 2026-2035. This growth is driven by increasing demand for outpatient immunosuppression and specialist nephrology care. These centres can provide a range of services including consultant led care, nursing support, dietitian support and social care. This allows for more structured monitoring and treatment of patients.
The growth of specialty infusion centres is also contributing to outpatient IV immunosuppressant treatments. This can reduce the need for patients to receive their treatment in hospitals. Clinics providing screening and management for nephrotic syndrome are becoming more relevant with increased awareness of diagnoses. The development of healthcare facilities within emerging markets will also provide opportunities to provide specialist care beyond large hospitals.
In August 2026, Travere Therapeutics reported Filspari commercial uptake concentrated in specialty nephrology centres, reflecting specialist-driven treatment adoption and preference for disease-specific care-delivery models over general-practice management approaches.
Regional Insights in the Nephrotic Syndrome Market
Regional Analysis:
Region | Major Country | Share within Region, 2025 (%) |
North America | United States | 84 |
Europe | Germany | 31 |
Asia Pacific | China | 38 |
LAMEA | Brazil | 58 |
North America: Advanced pharmaceutical infrastructure and specialty healthcare networks drive nephrotic syndrome market dominance substantially.
The North America nephrotic syndrome market is expected to grow at a CAGR of ~10.2% from 2026 to 2035. The US dominates the regional market and contributes ~84% of the total revenue. This is attributed to a large patient population, high prevalence of diabetes and hypertension, and excellent facilities for diagnosis and treatment. Additionally, there are well-established facilities for specialty nephrology. The high level of investment in healthcare for kidney disease, and early adoption of new therapies also helps. Specialist nephrology centres and kidney disease programmes help to provide coordinated care.
There is a strong drug innovation scene in North America; therefore, therapies will develop quickly. There is good infrastructure for clinical trials, as well as significant funding for research from the National Institutes of Health. This means there is better understanding of kidney disease. There is also insurance and reimbursement for new immunosuppressive therapies. In addition, many pharma companies have their headquarters in North America meaning they will be more engaged with the market. This means there is good infrastructure for treatment available, meaning there will be continued demand for advanced therapies and specialist care.
In April 2026, Travere Therapeutics announced FDA approval of Filspari for focal segmental glomerulosclerosis, following accelerated regulatory pathway reflecting unmet clinical need and substantial commercial opportunity in North American market.
USA: Large patient population and advanced healthcare infrastructure position USA as primary nephrotic syndrome market.
The USA Nephrotic Syndrome Market has a current value of ~USD 200 million in 2025 (approx. 50% of the 7 major markets combined). It is anticipated that the market will increase to ~USD 450-550 million by 2035, growing at a CAGR of 10.2% between 2026 and 2035. This is due to the country making up ~84% of revenue in North America, with a high population of patients requiring treatment, extensive healthcare spending and advanced diagnostic and therapeutic technologies.
The disease burden is driven by the high prevalence of diabetes, impacting ~37 million people in the USA. Chronic kidney disease caused by hypertension also impacts ~15 million people. Patients have access to treatment with Medicare covering immunosuppressants. There are well-established nephrology centres which can provide high level care to patients. There is significant investment into drugs for nephrotic syndrome due to the large patient population. Clinical trials are accessible with an easy process to recruit patients. There are lots of specialist health care professionals meaning there is a strong clinical trial development environment. This is also supported by the presence of many research institutions and pharmaceutical companies.
In April 2026, FDA approval of Filspari demonstrated rapid regulatory advancement and strong commercial uptake, with first-year sales reaching USD 141 million and validating market demand for novel mechanism-of-action therapies addressing focal segmental glomerulosclerosis.
Europe: Advanced renal-replacement infrastructure and expanding specialty pharmaceutical adoption drive European market growth substantially.
The Europe Nephrotic Syndrome Market is expected to grow at a rate of around 10.1% during the forecast period of 2026-2035. With Germany accounting for around 31% of the revenue generated in the European market due to its robust healthcare infrastructure, well-established presence of pharmaceutical research and wide-ranging kidney disease management programs. The overall Nephrotic Syndrome Market in the EU4 region (Germany, France, Italy and Spain) and in the UK was worth around USD 140 million in 2025.
A robust diagnostic infrastructure exists across the region, with kidney biopsy and electronic medical record facilities in place. This enables effective diagnosis, clinical evaluation and coordination between healthcare professionals. There is good coverage of immunosuppressive drugs and kidney therapies in the healthcare system, making treatment accessible to those of different socioeconomic backgrounds. With strong pharmaceutical development and well-established regulatory processes, new treatments can be developed and brought to market.
Ageing populations across Europe there is a growing need for diagnosis of Nephrotic Syndrome. Research partnerships and clinical trials have been established across the region, helping to improve understanding of the disease. Specialist kidney centres offer a range of services to aid diagnosis, treatment and monitoring.
In June 2026, Travere Therapeutics signed licensing agreement with Everest Medicines for European distribution of civorebrutinib, reflecting strategic focus on emerging-market expansion and geographic portfolio diversification across European nephrology specialists.
Asia-Pacific: Rising diabetes prevalence and healthcare infrastructure modernisation drive region fastest-growth substantially.
Asia Pacific will be the fastest growing region for the Nephrotic Syndrome Market growing at a CAGR of approximately 12.1% from 2026-2035. China will dominate the regional market, representing approximately 38% of revenue. This is due to a high number of diabetic patients in China (~140 million). Urbanisation and lifestyle changes are also driving an increase in diabetes and hypertension levels amongst Asian populations.
Furthermore, improvements in health care infrastructure and government funding for kidney disease initiatives are increasing the ability to diagnose and treat patients. A rise in domestic pharmaceutical companies and generic manufacturers are helping to lower costs. As healthcare spending and disposable income increases, more patients are able to receive specialist care. There is an increase in clinical trials taking place within Asia-Pacific due to high patient populations and developing regulatory processes. This means there will be more patients involved in research. Partnerships between global pharmaceutical companies and regional distributors will help to bring therapies to market.
Overall, Asia Pacific will grow significantly due to an increase in clinical trials within the region. Pharmaceutical companies are becoming aware of the high patient populations and developing regulations. More patients will become involved in research which will help develop therapeutics. Partnerships between global pharma companies and regional distributors will help bring therapies to market.
In June 2026, Chugai announced filing of new drug application in Japan for sparsentan indicated for immunoglobulin A nephropathy treatment, reflecting Asian-market expansion of novel mechanism-of-action therapies and regulatory approval acceleration across region.
Japan: Advanced healthcare infrastructure and specialty pharmaceutical adoption position Japan as significant Asian market.
The Japan Nephrotic Syndrome Market has shown a high growth rate of 9.8% during the forecast period from 2026 to 2035. This can be attributed to the demand for advanced therapies in kidney disease. Japan holds approximately 15% of total Asia-Pacific revenue. This can be attributed to the advanced diagnostic facilities, well established nephrology field and extensive healthcare coverage. In Japan, there is an ageing population causing demand for advancements in the diagnosis of kidney disease. The prevalence will vary depending on age and underlying condition.
Healthcare coverage for immunosuppressants means patients have access to well established treatments. Advancements in targeted therapies mean there are more opportunities for tailored management of disease. Japan has a strong regulatory system, clinical trial infrastructure and well established pharmaceutical industry which means new therapies can be developed. Specialist nephrology services are available.
Pharmaceutical partnerships and manufacturing within Japan are helping to improve the therapeutic landscape. Investment in research for kidney disease is increasing knowledge on nephrotic syndrome. This will help improve innovation in the clinic and increase access to advanced therapies. This will drive the development of the nephrotic syndrome market in Japan up until 2035.
In June 2026, Chugai filed new drug application in Japan for sparsentan for immunoglobulin A nephropathy, reflecting Asian regulatory approval acceleration and specialist-driven therapy adoption across region.
LAMEA: Emerging-market healthcare modernisation and rising diabetes prevalence drive region expansion substantially.
The LAMEA nephrotic syndrome market will grow at a CAGR of around 8.9% during the forecast period (2026-2035) due to better healthcare availability, increased awareness of kidney disorders and increased availability of drugs. Brazil makes up around 58% of the overall revenue, with more people developing diabetes along with increased urbanization and lifestyle related issues in the region. The growth of pharmaceutical companies and generic drug companies throughout Latin America is increasing the availability of affordable treatment options.
Investment from government into the management of chronic disease has increased the availability of diagnostics and treatment for nephrotic syndrome. Increased healthcare spending and disposable income within middle income countries has opened up new opportunities to increase specialist nephrology services. Increasing clinical trials are also increasing interest in patient populations in this region. Collaborations between global pharmaceutical and local distributors have improved market availability. Awareness campaigns and education of doctors has also increased diagnosis rates of previously under diagnosed patients, helping to develop the LAMEA nephrotic syndrome market in the long term.
In early 2026, regional healthcare system modernisation initiatives across Latin America expanded kidney disease screening and management programmes, creating demand for diagnostic testing and pharmaceutical interventions supporting nephrotic syndrome treatment access.
How Can Stakeholders Benefit from the Nephrotic Syndrome Market Report?
- The report offers a quantitative assessment of market segments, emerging trends, projections, and market dynamics for the period 2024 to 2035.
- The report presents comprehensive market research, including insights into key growth drivers, challenges, and potential opportunities.
- Porter's Five Forces analysis evaluates the influence of buyers and suppliers, helping stakeholders make strategic, profit-driven decisions and strengthen their supplier-buyer relationships.
- A detailed examination of market segmentation helps identify existing and emerging opportunities.
- Key countries within each region are analysed based on their revenue contributions to the overall market.
- The positioning of market players enables effective benchmarking and provides clarity on their current standing within the industry.
- The report covers regional and global market trends, major players, key segments, application areas, and strategies for market expansion.

